Developing a vaccine for Type 1 diabetes through targeting enteroviral infections

Expert Review of Vaccines

Volumn 13, Issue 8, 2014, Pages 989-999

  Hyöty, Heikki ^a,b   Knip, Mikael ^c,d,e,f  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b PIRKANMAA HOSPITAL DISTRICT   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^e FOLKHÄLSAN RESEARCH CENTER   (Finland)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antiviral drugs; Enterovirus; Type 1 diabetes; Vaccine

Indexed keywords

ANTIVIRUS AGENT; DIABETES VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS VACCINE;

DISEASE ASSOCIATION; ENTEROVIRUS; ENTEROVIRUS INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; COMPLICATION; DIABETES MELLITUS, TYPE 1; DRUG DEVELOPMENT; ENTEROVIRUS INFECTIONS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MEDICAL RESEARCH; TRENDS;

BIOMEDICAL RESEARCH; DIABETES MELLITUS, TYPE 1; DRUG DISCOVERY; ENTEROVIRUS INFECTIONS; HUMANS; VIRAL VACCINES;

EID: 84904316858     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.933078     Document Type: Review

References (85)

1. Pociot F, Akolkar B, Concannon P, et al. Genetics of type 1 diabetes: what's next? Diabetes 2010;59(7): 1561-71
2. Knip M, Veijola R, Virtanen SM, et al. Environmental triggers and determinants of type 1 diabetes. Diabetes 2005;54(Suppl 2): S125-36
3. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309(23): 2473-9
4. Hyöty H, Taylor KW. The role of viruses in human diabetes. Diabetologia 2002; 45(10): 1353-61
5. Yoon JW, Jun HS. Viruses cause type 1 diabetes in animals. Ann NY Acad Sci 2006;1079: 138-46
6. Rasmussen T, Witsø E, Tapia G, et al. Self-reported lower respiratory tract infections and development of islet autoimmunity in children with the type 1 diabetes high-risk HLA genotype: the MIDIA study. Diabetes Metab Res Rev 2011;7.834-7
7. Beyerlein A, Wehweck F, Ziegler AG, Pflueger M. Respiratory infections in early life and the development of islet autoimmunity in children at increased type 1 diabetes risk: evidence from the BABYDIET study. JAMA Pediatr 2013;167: 800-7
8. Nurminen N, Oikarinen S, Hyöty H. Virus infections as potential targets of preventive treatments for type 1 diabetes. Rev Diabet Stud 2012;9: 260-71
9. Hober D, Alidjinou EK. Enteroviral pathogenesis of type 1 diabetes: queries and answers. Curr Opin Infect Dis 2013;26(3): 263-9
10. Racaniello VR. One hundred years of poliovirus pathogenesis. Virology 2006; 344(1): 9-16
11. Chapman NM, Kim KS. Persistent coxsackievirus infection: enterovirus persistence in chronic myocarditis and dilated cardiomyopathy. Curr Top Microbiol Immunol 2008;323: 275-92
12. Tam PE, Schmidt AM, Ytterberg SR, Messner RP. Duration of virus persistence and its relationship to inflammation in the chronic phase of coxsackievirus B1-induced murine polymyositis. J Lab Clin Med 1994;123: 346-56
13. Feuer R, Ruller CM, An N, et al. Viral persistence and chronic immunopathology in the adult central nervous system following Coxsackievirus infection during the neonatal period. J Virol 2009;83: 9356-69
14. MacLennan C, Dunn G, Huissoon AP, et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 2004;363(9420): 1509-13
15. Mueller S, Wimmer E, Cello J. Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event. Virus Res 2005;111: 175-93
16. Kaufman DL, Erlander MG, Clare-Salzler M, et al. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 1992;89(1): 283-92
17. Härkönen T, Paananen A, Lankinen H, et al. Enterovirus infection may induce humoral immune response reacting with islet cell autoantigens in humans. J Med Virol 2003;69(3): 426-40
18. Horwitz MS, Bradley LM, Harbertson J, et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998;4(7): 781-5
19. Ylipaasto P, Klingel K, Lindberg AM, et al. Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells. Diabetologia 2004;47: 225-39
20. Barboni E, Manocchio J. Alterazioni pancreatiche in bovini con diabete mellito post-aftoso. Arch Vet Ital 1962;13: 477-89
21. Jun HS, Kang Y, Notkins AL, Yoon JW. Gain or loss of diabetogenicity resulting from a single point mutation in recombinant encephalomyocarditis virus. J Virol 1997;71(12): 9782-5
22. Jun HS, Yoon JW. The role of viruses in type I diabetes: two distinct cellular and molecular pathogenic mechanisms of virus-induced diabetes in animals. Diabetologia 2001;44(3): 271-85 • Describes the basic pathogenetic mechanisms of virus-induced diabetes in the most widely studied animal model.
23. Jun HS, Yoon SW, Kang Y, et al. Cloning and expression of the VP1 major capsid protein of diabetogenic encephalomyocarditis (EMC) virus and prevention of EMC virus-induced diabetes by immunization with the recombinant VP1 protein. J Gen Virol 1995;76: 2557-1566
24. Notkins AL, Yoon JW. Virus-induced diabetes in mice prevented by a live attenuated vaccine. N Engl J Med 1982; 306(8): 486
25. Toniolo A, Onodera T, Jordan G, et al. Virus-induced diabetes mellitus. glucose abnormalities produced in mice by the six members of the Coxsackie B virus group. Diabetes 1982;31(6): 496-9
26. Jaidane H, Sane F, Gharbi J, et al. Coxsackievirus B4 and type 1 diabetes pathogenesis: contribution of animal models. Diabetes Metab Res Rev 2009;25: 591-603 • Summary of findings from animal models used to study the mechanisms of enterovirus-induced diabetes.
27. Flodström M, Tsai D, Fine C, et al. Diabetogenic potential of human pathogens uncovered in experimentally permissive beta-cells. Diabetes 2003;52(8): 2025-34
28. Tracy S, Drescher KM. Coxsackievirus infections and NOD mice: relevant models of protection from, and induction of, type 1 diabetes. Ann NY Acad Sci 2007;1103: 143-51
29. Yoon JW, London WT, Curfman BL, et al. Coxsackie virus B4 produces transient diabetes in nonhuman primates. Diabetes 1986;35: 712-16
30. Anagandula M, Richardson SJ, Oberste MS, et al. Infection of human islets of langerhans with two strains of coxsackie B virus serotype 1: assessment of virus replication, degree of cell death and induction of genes involved in the innate immunity pathway. J Med Virol 2014;86: 1402-11
31. Hodik M, Lukinius A, Korsgren O, Frisk G. Tropism analysis of two Coxsackie B5 strains reveals irus growth in human primary pancreatic islets but not in exocrine cell clusters in vitro. Open Virol J 2013;7: 49-56
32. Hämäläinen S, Nurminen N, Ahlfors H, et al. Coxsackievirus B1 reveals strain specific differences in plasmacytoid dendritic cell mediated immunogenicity. J Med Virol 2014;86: 1412-20
33. Jenson AB, Rosenberg HS, Notkins AL. Pancreatic islet-cell damage in children with fatal viral infections. Lancet 1980;2: 354-8
34. Bissel SJ, Winkler CC, Deltondo J, et al. Coxsackievirus B4 myocarditis and meningoencephalitis in newborn twins. Neuropathology In press
35. Richardson SJ, Willcox A, Bone AJ, et al. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 2009;52: 1143-51
36. Richardson SJ, Leete P, Dhayal S, et al. Evaluation of the fidelity of immunolabelling obtained with clone 5D8/1, a monoclonal antibody directed against the enteroviral capsid protein, VP1, in human pancreas. Diabetologia 2014;57(2): 392-401
37. Krogvold L, Edwin B, Buanes T, et al. Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia 2014;57(4): 841-3
38. Krogvold L, Edwin B, Buanes T, et al. Enterovirus in pancreatic islets at the diagnosis of human type 1 diabetes: results from the DiViD-study. Scientific Sessions, American Diabetes Association, Chicago, 2013 •• This is the first study confirming the presence of enterovirus in the pancreas of the majority of Type 1 diabetic patients using sensitive RT-PCR.
39. Foulis AK, McGill M, Farquharson MA, Hilton DA. A search for evidence of viral infection in pancreases of newly diagnosed patients with IDDM. Diabetologia 1997; 40(1): 53-61
40. Yoon JW, Austin M, Onodera T, Notkins AL. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979;300: 1173-9
41. Dotta F, Censini S, van Halteren AG, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A 2007;104: 5115-20
42. Oikarinen M, Tauriainen S, Honkanen T, et al. Analysis of pancreas tissue in a child positive for islet cell antibodies. Diabetologia 2008;51: 1796-802
43. Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987;2(8573): 1423-7
44. Richardson SJ, Leete P, Bone AJ, et al. Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of mcl-1. Diabetologia 2013;56(1): 185-93
45. Gamble DR, Taylor KW, Cumming H. Coxsackie viruses and diabetes mellitus. Br Med J 1973;4: 260-2
46. Gamble DR, Kinsley ML, FitzGerald MG, et al. Viral antibodies in diabetes mellitus. Br Med J 1969;3: 627-30
47. Green J, Casabonne D, Newton R. Coxsackie B virus serology and type 1 diabetes mellitus: a systematic review of published case-control studies. Diabet Med 2004;21: 507-14
48. Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. Br Med J 2011;342:d35 •• The most recent meta-analysis on the risk association between enterovirus infections and Type 1 diabetes (T1D).
49. Tapia G, Cinek O, Rasmussen T, et al. Human enterovirus RNA in monthly fecal samples and islet autoimmunity in Norwegian children with high genetic risk for type 1 diabetes: the MIDIA study. Diabetes Care 2011;34: 151-5
50. Simonen-Tikka ML, Pflueger M, Klemola P, et al. Human enterovirus infections in children at increased risk for type 1 diabetes: the Babydiet study. Diabetologia 2011; 54(12): 2995-3002
51. Oikarinen M, Tauriainen S, Honkanen T, et al. Detection of enteroviruses in the intestine of type 1 diabetic patients. Clin Exp Immunol 2008;151(1): 71-5
52. Oikarinen M, Tauriainen S, Oikarinen S, et al. Type 1 diabetes is associated with enterovirus infection in gut mucosa. Diabetes 2012;61: 687-91
53. Mercalli A, Lampasona V, Klingel K, et al. No evidence of enteroviruses in the intestine of patients with type 1 diabetes. Diabetologia 2012;55(9): 2479-88
54. Viskari HR, Roivainen M, Reunanen A, et al. Maternal first-trimester enterovirus infection and future risk of type 1 diabetes in the exposed fetus. Diabetes 2002;51(8): 2568-71
55. Viskari H, Knip M, Tauriainen S, et al. Maternal enterovirus infection as a risk factor for type 1 diabetes in the exposed offspring. Diabetes Care 2012;35(6): 1328-32
56. Viskari HR, Koskela P, Lonnrot M, et al. Can enterovirus infections explain the increasing incidence of type 1 diabetes? Diabetes Care 2000;23: 414-16
57. Viskari H, Ludvigsson J, Uibo R, et al. Relationship between the incidence of type 1 diabetes and enterovirus infections in different European populations: results from the EPIVIR project. J Med Virol 2004;72: 610-17
58. Viskari H, Ludvigsson J, Uibo R, et al. Relationship between the incidence of type 1 diabetes and maternal enterovirus antibodies: time trends and geographical variation. Diabetologia 2005;48: 1280-7
59. Larsson PG, Lakshmikanth T, Svedin E, et al. Previous maternal infection protects offspring from enterovirus infection and prevents experimental diabetes development in mice. Diabetologia 2013;56(4): 867-74
60. Laitinen OH, Honkanen H, Pakkanen O, et al. Coxsackievirus B1 is associated with the induction of beta-cell autoimmunity that portends type 1 diabetes. Diabetes 2014;63: 446-55 •• The first systematic survey carried out to identify the types of enteroviruses showing association with T1D.
61. Oikarinen S, Tauriainen S, Hober D, et al. Virus antibody survey in different European populations indicates risk association between coxsackievirus B1 and type 1 diabetes. Diabetes 2014;63: 655-62 •• Validation of the risk association between coxsackievirus B1 and T1D identified in Reference [46].
62. Cabrera-Rode E, Sarmiento L, Tiberti C, et al. Type 1 diabetes islet associated antibodies in subjects infected by echovirus 16. Diabetologia 2003;46: 1348-53
63. Paananen A, Ylipaasto P, Rieder E, et al. Molecular and biological analysis of echovirus 9 strain isolated from a diabetic child. J Med Virol 2003;69(4): 529-37
64. Williams CH, Oikarinen S, Tauriainen S, et al. Molecular analysis of an echovirus 3 strain isolated from an individual concurrently with appearance of islet cell and IA-2 autoantibodies. J Clin Microbiol 2006;44(2): 441-8
65. Moore M, Kaplan MH, McPhee J, et al. Epidemiologic, clinical, and laboratory features of Coxsackie B1-B5 infections in the United States, 1970-79. Public Health Rep 1984;99(5): 515-22
66. Sadeharju K, Knip M, Hiltunen M, et al. The HLA-DR phenotype modulates the humoral immune response to enterovirus antigens. Diabetologia 2003;46(8): 1100-5
67. Smyth DJ, Cooper JD, Bailey R, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006;38: 617-19
68. Heinig M, Petretto E, Wallace C, et al. A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature 2010;467(7314): 460-4
69. Wang Y, Shaked I, Stanford SM, et al. The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity 2013;39(1): 111-22
70. Staeva TP, Chatenoud L, Insel R, Atkinson MA. Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes 2013;62(1): 9-17
71. Donath MY, Hess C, Palmer E. What is the role of autoimmunity in type 1 diabetes? a clinical perspective. Diabetologia 2014;57(4): 653-5
72. Knip M, Virtanen SM, Seppä K, et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med 2010;363(20): 1900-8
73. Skog O, Korsgren S, Melhus A, Korsgren O. Revisiting the notion of type 1 diabetes being a T-cell-mediated autoimmune disease. Curr Opin Endocrinol Diabetes Obes 2013;20(2): 118-23
74. Willcox A, Richardson SJ, Bone AJ, et al. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2008; 155(2): 173-81
75. In't Veld P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets 2011;3(4): 131-8
76. Yang DH, Ho LJ, Lai JH. Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. World J Gastroenterol 2014; 20(11): 2962-70
77. Thomassen YE, van 't Oever AG, van Oijen MG, et al. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PLoS One 2013;8(12):e83374
78. Larsson PG, Tadepally L, Laitinen OH, et al. A preclinical study on the efficacy and safety of a new vaccine against coxsackievirus B1 reveals no risk for accelerated diabetes development. EUROPIC meeting, Belgium, 2014 •• Preclinical safety and efficacy study of formalin-inactivated vaccine against coxsackievirus B1.
79. Koho T, Koivunen MLR, Oikarinen S, et al. Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice. Antiviral Res 2014;104: 93-101 •• Describes technologies for efficient production of virus-like particles for vaccines against group B coxsackieviruses.
80. Fohlman J, Ilbäck NG, Friman G, Morein B. Vaccination of Balb/c mice against enteroviral mediated myocarditis. Vaccine 1990;8(4): 381-4
81. Toniolo A, Falcone V, Bernasconi C, et al. DNA immunization of mice against the VP1 capsid protein of coxsackievirus B4. Scand J Immunol 2002;56(5): 448-55
82. Dan M, Chantler JK. A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection. J Virol 2005;79(14): 9285-95
83. Kim JY, Jeon ES, Lim BK, et al. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine 2005;23(14): 1672-9
84. Lan J, Gao Z, Xiong H, et al. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination. Vaccine 2011;29(40): 6894-902
85. Coppieters KT, Wiberg A, von Herrath MG. Viral infections and molecular mimicry in type 1 diabetes. APMIS 2012;120(12): 941-9